CD37 is a tetraspanin family plasma membrane protein involved in cell membrane organization and cosignaling. CD37 is selectively expressed on mature B cells and has limited or no expression on other hematopoietic cells such as T cells and NK cells, granulocytes, monocytes and dendritic cells. CD37 is present on the cell surface, but also on endosomes and exosomes, which contributes to intracellular trafficking and immunomodulation.1-3
The biologic function of CD37 is not yet fully elucidated, however recent advances suggest the protein plays a role in pro-survival and pro-apoptotic signaling via the PI3K/AKT pathway. In addition, it controls IL-6 receptor signaling through interaction with SOCS3. 1,2
On the basis of an expression pattern largely overlapping CD20, CD37 was one of the first proteins explored as therapeutic target in non-Hodgkin lymphomas in the late 1980s and a renewed interest in this target has supported the development of new therapeutic agents targeting CD37.2
In preclinical settings, dual-epitope bispecific DuoHexaBody®-CD37 has been shown to induce potent in vivo and in vitro anti-tumor activity.1
The site you have requested is intended to provide information for healthcare professionals residing in the US or Puerto Rico.
I am a licensed healthcare professional residing in the US or Puerto Rico.
I am not a licensed healthcare professional residing in the US or Puerto Rico.
Contact Medical Information
For All Other Information